Drug class profile · refreshed daily from federal data

Adrenergic Agonist

6 molecules in this class, $182.9M combined CY2024 Part D spend across 875K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Sep 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Adrenergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $182.9Mcombined across class
Total Rx claims: 875K718K unique beneficiaries
Generic mfrs (active): 6across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Epinephrine

Brand: Adrenalin · 875K Part D claims (CY24) · 718K beneficiaries · First FDA approval: 1987-12-22

6 generic mfrs 0 plans require PA Discontinued

Low NADAC$1.19

→

Avg plan cost$152.83

Part D spend $182.9M 128× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Adrenalin (Epinephrine)

— Part D claims (CY24) · First FDA approval: 2018-09-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Adrenalin(R)

— Part D claims (CY24) · First FDA approval: 2018-09-19

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Auvi-Q

— Part D claims (CY24) · First FDA approval: 2012-11-15

Brand-only (no generics)

Low NADAC$309.38

→

Avg plan cost$309.59

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Epinephrine 0.15 Pediatrics

Brand: Epinephrine Pediatrics · — Part D claims (CY24) · First FDA approval: 2010-04-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Epinephrine 0.3 Adults

— Part D claims (CY24) · First FDA approval: 2010-04-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.